Abstract
Objective: To gain insight into the current management of patients with type 2 diabetes mellitus by Canadian primary care physicians. Method: A total of 479 primary care physicians from across Canada submitted data on 5123 type 2 diabetes patients whom they had seen on a single day on or around World Diabetes Day, November 14, 2012. Results: Mean glycated hemoglobin (A1C) was 7.4%, low-density lipoprotein (LDL-C) was 2.1 mmol/L and blood pressure (BP) was 128/75 mm Hg. A1C ≤7.0% was met by 50%, LDL-C ≤2.0 mmol/L by 57%, BP <130/80 mm Hg by 36% and the composite triple target by 13% of patients. Diet counselling had been offered to 38% of patients. Of the 87% prescribed antihyperglycemic agents, 18% were on 1 non-insulin antihyperglycemic agent (NIAHA) (85% of which was metformin), 15% were on 2 NIAHAs, 6% were on ≥3 NIAHAs, 19% were on insulin only and 42% were on insulin + ≥1 NIAHA(s). Amongst the 81% prescribed lipid-lowering therapy, 88% were on monotherapy (97% of which was a statin). Among the 83% prescribed antihypertensive agents, 39%, 34%, 21% and 6% received 1, 2, 3 and >3 drugs, respectively, with 59% prescribed angiotensin-converting enzyme inhibitors and 35% angiotensin II receptor blockers. Conclusions: The Diabetes Mellitus Status in Canada survey highlights the persistent treatment gap associated with the treatment of type 2 diabetes and the challenges faced by primary care physicians to gain glycemic control and global vascular protection in these patients. It also reveals a higher use of insulin therapy in primary care practices relative to previous surveys. Practical strategies aimed at more effectively managing type 2 diabetes patients are urgently needed.
Original language | English |
---|---|
Pages (from-to) | 82-89 |
Number of pages | 8 |
Journal | Canadian Journal of Diabetes |
Volume | 37 |
Issue number | 2 |
DOIs | |
Publication status | Published - Apr 2013 |
Bibliographical note
Funding Information:The Diabetes Mellitus Status in Canada (DM-SCAN) survey was made possible through the support of Merck Canada Inc . The opinions expressed in this material are those of the authors and do not necessarily reflect the views of Merck Canada Inc.
Funding Information:
LAL has received honouraria or research support from Amgen , AstraZeneca , Boehringer Ingelheim , Bristol-Myers Squibb , Eli Lilly , GlaxoSmithKline , Janssen , Merck , Novartis , Novo Nordisk , Sanofi , Servier and Takeda . LB has received honouraria or research support from AstraZeneca , Bristol-Myers Squibb , Eli Lilly , Janssen , Merck , Novo Nordisk and Sanofi . CKB has received honouraria or research support from AstraZeneca , Boehringer Ingelheim , Bristol-Myers Squibb , Eli Lilly , Merck , Novartis , Novo Nordisk , Pfizer and Sanofi . AYC has received honouraria or research support from Abbott , AstraZeneca - Bristol-Myers Squibb , Becton Dickinson , Eli Lilly , Eli Lilly , Lifescan , Merck , Novo Nordisk , Sanofi and Servier . KGD has received honouraria or research support from GlaxoSmithKline , Lifescan , Lilly , Merck , Novo Nordisk and Sanofi . J-ME has received honouraria or research support from Merck . CF has received honouraria or research support from Amgen , AstraZeneca , Boehringer Ingelheim , Bristol-Myers Squibb , Forrest , Janssen , Sanofi , Takeda and Valeant . LG has no conflicts of interest to declare. SBH has received honouraria or research support from AstraZeneca - Bristol-Myers Squibb , Boehringer Ingelheim-Eli Lilly , Janssen , Merck , NovoNordisk , Roche , Sanofi and Takeda . PL has received honouraria or research support from AstraZeneca , Boehringer Ingelheim , Eli Lilly , Merck , NovoNordisk , Sanofi and Takeda . TR has received honouraria or research support from AstraZeneca , Boehringer Ingelheim , Bristol-Myers Squibb , Eli Lilly , GlaxoSmithKline , Merck , Novartis , NovoNordisk and Sanofi . MT has no conflicts of interest to declare. HT has no conflicts of interest to declare. RTT has received honouraria or research support from Abbott , AstraZeneca , Bristol-Myers Squibb-AstraZeneca , Boehringer Ingelheim , Merck , PharmaSmart and Sanofi . DW has no conflicts of interest to declare. VW has received honouraria or research support from AstraZeneca , Boehringer Ingelheim , Bristol-Myers Squibb , Eli Lilly , Forrest , Janssen , Merck , Novo Nordisk and Sanofi . J-FY has received honouraria or research support from AstraZeneca , Boehringer Ingelheim , Bristol-Myers Squibb , Eli Lilly , Janssen , Merck , Novo Nordisk , Sanofi and Takeda . AL has received honouraria or research support from Actelion , AstraZeneca , Aventis , Bayer , Biovail , Boston Scientific , Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership , Cordis , Guidant , Medtronics , Merck , Millennium Pharmaceuticals , Ortho Biotec , Oryx , Pfizer , Roche , Sanofi-Synthelabo , Schering Key Corporation , Servier , The Medicines Company and United Therapeutics .
ASJC Scopus Subject Areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology